Ensol Biosciences Inc. (XKON:A140610) announced a private placement of 873,010 convertible preferred shares at an issue price of KRW 12,600 per share for gross proceeds of KRW 10,999,926,000 on April 22, 2019. The transaction will involve participation from Melon - Widwin New Technology Fund 1 for 285,714 shares, Melon - Widwin New Technology Fund 2 for 349,206 shares, Ace Susung Venture Capital Hedge Fund 5 for 79,365 shares, and another investor. The transaction is expected to close on April 30, 2019. The shares will be convertible into 873,010 common shares from July 30, 2019 to July 29, 2022. The shares will be issued at a premium and through third party allotment method.